Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.95+0.10 (+3.33%)
Close on Nov 18, 2026Market cap $242.04MP/E –Yield –
Lexeo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Lexeo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$95.12M. For fiscal 2025 it was -$109.26M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$109.26M | – |
| FY2024 | Dec 31, 2024 | -$105.77M | – |
| FY2023 | Dec 31, 2023 | -$68.51M | – |
| FY2022 | Dec 31, 2022 | -$60.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.33M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.81M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.54M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.48M | – |
See a number that looks wrong?